Bisamide sarcomere activating compounds and uses thereof
Luke Ashcraft, San Francisco, CA (US); Alessandro Boezio, Somerville, MA (US); John Butler, Somerville, MA (US); Aroop Chandra, South San Francisco, CA (US); Chihyuan Chuang, Millbrae, CA (US); Scott E. Collibee, San Carlos, CA (US); Mikkel Debenedetto, Shrewsbury, MA (US); Vincent Dimassa, South San Francisco, CA (US); Russell Graceffa, Hampton, NH (US); Justin Malinowski, Charlestown, MA (US); David Moebius, Westwood, MA (US); Bradley P. Morgan, Moraga, CA (US); Joshua Payette, Santa Clara, CA (US); Antonio Romero, San Mateo, CA (US); David St. Jean, Jr., Natick, MA (US); Richard Vargas, Bedford, MA (US); John Yeoman, Medford, MA (US); Hanmo Zhang, Chestnut Hill, MA (US); Alan Cheng, San Francisco, CA (US); Felix Gonzalez Lopez De Turiso, Cambridge, MA (US); and Michael Garrett Johnson, San Francisco, CA (US)
Assigned to AMGEN INC., Thousand Oaks, CA (US); and CYTOKINETICS, INC., South San Francisco, CA (US)
Filed by Amgen Inc., Thousand Oaks, CA (US); and Cytokinetics, Inc., South San Francisco, CA (US)
Filed on Feb. 15, 2022, as Appl. No. 17/672,594.
Application 17/068,518 is a division of application No. 16/833,336, filed on Mar. 27, 2020, granted, now 10,899,746, issued on Jan. 26, 2021.
Application 16/833,336 is a division of application No. 16/129,862, filed on Sep. 13, 2018, granted, now 10,723,720, issued on Jul. 28, 2020.
Application 17/672,594 is a continuation of application No. 17/068,518, filed on Oct. 12, 2020, granted, now 11,299,479.
Claims priority of provisional application 62/557,846, filed on Sep. 13, 2017.
Prior Publication US 2022/0281850 A1, Sep. 8, 2022
